MMR/MMRV VACCINES
VAERS REPORTS SINCE 1989, AS OF 2/19/19

- 31,820 emergency room visits
- 8,800 listed as serious
- 6,731 hospitalized
- 415 deaths

LESS THAN 1% OF VACCINE ADVERSE REACTIONS ARE EVER REPORTED

http://www.medalerts.org/vaersdb/index.php
How do we know that 99% of adverse events following vaccines go unreported, if they were... never reported?

- 2010 Harvard Pilgrim study, in association with the CDC: “This research project was funded to improve the quality of vaccination programs by improving the quality of physician adverse vaccine event detection and reporting to the national Vaccine Adverse Event Reporting System (VAERS)

- What they found: “Although 25% of ambulatory patients experience an adverse drug event, less than 0.3% of all adverse drug events and 1-13% of serious events are reported to the Food and Drug Administration (FDA). Likewise, fewer than 1% of vaccine adverse events are reported.” (bolding mine)

- What was the CC’s response to this information?

  Although the CDC engaged consultants for this project, they became inexplicably “unavailable.”

  “Unfortunately, there was never an opportunity to perform system performance assessments because the necessary CDC contacts were no longer available and the CDC consultants responsible for receiving data were no longer responsive to our multiple requests to proceed with testing and evaluation.”

**SIDE EFFECTS**

The following adverse reactions are listed in decreasing order of severity, without regard to causality, within each body system category and have been reported during clinical trials, with use of the marketed vaccine, or with use of monovalent or bivalent vaccine containing measles, mumps, or rubella:

**Body as a Whole**

- Panniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability.

**Cardiovascular System**

- Vasculitis.

**Digestive System**

- Pancreatitis; diarrhea; vomiting; parotitis; nausea.

**Endocrine System**

- Diabetes mellitus.

**Hemic and Lymphatic System**

- Thrombocytopenia (see WARNINGS AND PRECAUTIONS; Thrombocytopenia); purpura; regional lymphadenopathy; leukocytosis.

**Immune System**

- Anaphylaxis and anaphylactoid reactions have been reported as well as related phenomena such as angioneurotic edema (including peripheral or facial edema) and bronchial spasm in individuals with or without an allergic history.

**Musculoskeletal System**

- Arthritis; arthralgia; myalgia.

- Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children.

- Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed chronic joint symptoms.

- Following vaccination in children, reactions in joints are uncommon and generally of brief duration. In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (children: 0-3%, women: 12-26%), and the reactions tend to be more marked and of longer duration. Symptoms may persist for a matter of months or on rare occasions for years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and in adult women. Even in women older than 35 years, these reactions are generally well tolerated and rarely interfere with normal activities.

**Nervous System**

- Encephalitis; encephalopathy; measles inclusion body encephalitis (MIBE) (see CONTRAINDICATIONS); subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia.
Adult women have up to 26% risk of MMR-triggered arthritis/arthralgia, which can be severe and long-term.

“In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (children: 0-3%; women: 12-26%), and the reactions tend to be more marked and of longer duration.”

https://www.merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf
DOES VAERS HIDE REPORTED SEIZURE REACTIONS TO MMR-CONTAINING VACCINES?

Reports to VAERS, accessed via medalerts.org as of 3/24/18

• **294** reports where Symptom is Seizure or Seizure anoxic or Seizure cluster or Seizure like phenomena
• **160** reports Epilepsy or Epileptic encephalopathy
• **32** reports clonic convulsion or clonus
• **22** reports partial seizures
• **15** reports complex partial seizures
• **12** reports infantile spasms
• **66** reports Myoclonic epilepsy or Myoclonus
• **79** reports Tonic clonic movements or Tonic convulsion
• **1,040** reports tremor or tremor neonatal
• **3,279** reports Convulsion or Convulsion in childhood or Convulsion neonatal or Convulsions local
• **259** reports encephalitis
• **134** reports encephalopathy